如何应对继发性和治疗相关急性髓系白血病
该综述指出继发性AML(sAML)较原发AML患者年龄更大、对细胞毒化疗更耐药、复发率更高且预后更差。sAML在生物学和临床上具有异质性,其中继发于既往治疗过的血液病(ts-AML)及<55岁患者预后最差。尽管CPX-351已获批,长期结局仍不佳,靶向免疫治疗因克隆演化难以持久缓解,未来方向为CAR T细胞或双特异性抗体桥接异基因移植并增强移植物抗肿瘤效应。
要点
- sAML较原发AML更耐药、复发率高、预后差,ts-AML和<55岁亚组结局最差
- CPX-351获批后长期结局仍不理想,需创新策略
- 靶向免疫治疗易因克隆演化失效,CAR T或双特异性抗体桥接移植是潜在方向
核心结论
- sAML较原发AML预后更差,当前治疗结局不理想,存在未满足的创新治疗需求。
- 未来进展可能依赖CAR T细胞或双特异性抗体桥接异基因移植,并增强移植物抗肿瘤效应。
研究设计与样本
- 综述,总结继发性及治疗相关AML的临床结局与治疗策略。
主要发现
- sAML较原发AML患者年龄更大、对细胞毒化疗独立更耐药、复发率更高、预后更差。
- sAML在WHO亚组内仍具生物学和临床异质性。
- sAML继发于既往治疗过的血液病(ts-AML)及<55岁患者结局最差。
- 尽管CPX-351获批,该高危疾病长期结局仍不佳。
- 对强化化疗的耐药机制导致复发,靶向免疫治疗因克隆复杂快速演化难以提供长期缓解。
临床怎么用
- 应关注sAML高危亚组(ts-AML、<55岁)的识别与创新治疗策略。
- 可考虑CAR T细胞或双特异性抗体桥接异基因移植,并探索增强移植物抗肿瘤效应的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary acute myelogenous leukaemia (AML), as compared to de novo AML, occurs in the more elderly population, is independently more resistant to cytotoxic chemotherapy, has a higher relapse rate, and a worse prognosis. Secondary AML (sAML) is a heterogeneous disease, both biologically and clinically, even within the World Health Organization subgroups of sAML. Outcomes are the poorest in subgroups with sAML arising from an antecedent haematologic disorder which has been previously treated (ts-AML), and sAML in patients <55 years of age. This review describes the suboptimal outcomes of contemporary therapy, to support the notion of an unmet need for innovative treatment strategies in sAML. Despite the recent approval of CPX-351, long-term outcomes for this high-risk disease remain dismal. Resistance mechanisms to intensive chemotherapy contribute to relapse. Targeted immune therapy may avoid multidrug resistance mechanisms, but are unlikely to provide long-term remission due to a complex and rapidly evolving clonal disease profile. Advances for sAML will likely be accomplished by CAR T cell therapy or bispecific antibodies providing a bridge to allogeneic stem cell transplantation. Therefore, focus should be placed on novel strategies that can augment the untargeted effector function of allogeneic grafts.
引用
- Oliai C, Schiller G. How to address second and therapy-related acute myelogenous leukaemia. Br J Haematol. 2020. PMID: 31863469. doi:10.1111/bjh.16354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。